When standard cancer treatment stops working, patients face critical decisions about accessing additional treatment pathways through specialized oncology teams, clinical trial networks, molecular tumor boards, and comprehensive second-opinion services that evaluate genomic profiles and emerging therapies. TL;DR Seven in 10 people now survive cancer five years or longer, but treatment resistance requires expert evaluation of additional options including clinical trials, genomi